Citizens Maintains Market Outperform on CRISPR Therapeutics (CRSP) Despite Casgevy Slowdown

CRISPR Therapeutics AG (NASDAQ:CRSP) ranks among the best short squeeze stocks to buy right now. Citizens reaffirmed its ...
Fintel on MSN

Chardan Capital Maintains CRISPR Therapeutics (CRSP) Buy Recommendation

Fintel reports that on November 26, 2025, Chardan Capital maintained coverage of CRISPR Therapeutics (NasdaqGM:CRSP) with a Buy recommendation. Analyst Price Forecast Suggests 49.92% Upside As of ...
Nasdaq

Should CRSP Stock Be in Your Portfolio Pre-Q3 Earnings?

CRISPR Therapeutics CRSP is expected to report third-quarter 2025 earnings later this week. The Zacks Consensus Estimate for quarterly sales is pegged at $6.71 million, while that for earnings is ...
Nasdaq

CRISPR Therapeutics AG (CRSP) Falls More Steeply Than Broader Market: What Investors Need to Know

CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $60.62, moving -2.38% from the previous trading session. The stock fell short of the S&P 500, which registered a loss of 0.55% for ...